News | February 06, 2024
Sun Pharma Advanced Research Company Q3 FY24 loss at Rs. 99.65 Cr
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The IND application supports the next phase of development of SBO-154
SPARC to receive 55% equity in Tiller Therapeutics
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Subscribe To Our Newsletter & Stay Updated
